ada.enesco, Author at European Medical Journal - Page 19 of 65

Urine Tumour DNA Could Guide Therapeutic Decisions in Bladder Cancer

Profiling urine tumour DNA at baseline and after 3 months of treatment could identify whether patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer might not benefit from systemic immunotherapy.

Chronic Inflammation Linked to Increased Affective Disorders

Chronic exposure to systemic inflammation may be associated to a greater risk of affective disorders.

Can Post-Treatment MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy?

Pathologic complete response was accurately predicted by post-treatment MRI in patients with early triple-negative breast cancer having undergone neoadjuvant chemoimmunotherapy.

Parkinson’s Dementia Trial: Does Ambroxol Work Biologically and Clinically?

Ambroxol increased enzyme levels in Parkinson’s dementia patients, but showed no cognitive benefit in a year-long trial.

Hyperbaric Oxygen Therapy Leads Diabetic Foot Ulcer Treatment Rankings in New Meta-Analysis

Hyperbaric oxygen therapy ranks highest for healing diabetic foot ulcers but may raise amputation risk, new network meta-analysis reveals.

Study Links Bifidobacterium Deficit in Infants in the USA to Gut Dysbiosis

One in four U.S. infants lacks Bifidobacterium, a key gut microbe essential for immune and metabolic health.

New Antifungal Medication Shows Promise Against Resistant Invasive Fungal Disease

Early trial data show that olorofim may offer a valuable new option for patients with resistant invasive fungal infections.

Mycoplasma Pneumoniae Epidemic Strains ICUs Amid Atypical Presentations

High ICU admission rates and atypical features marked France’s recent M. pneumoniae epidemic, especially in those without early macrolide therapy.

Updated EAU Guidelines Transform Bladder Cancer Management

The guidelines endorse adjuvant nivolumab for patients with pT3/4 and/or pN+ disease who are unsuitable for, or have declined, cisplatin-based chemotherapy.

Dupilumab Linked to Higher Lymphoma Risk in Patients with Asthma

Dupilumab was associated with increased lymphoma risk but lower overall mortality in a large asthma cohort study.